U.S. Patent Protects EEG-Guided Sedation Safety Technology

Beachwood, Ohio (August 5, 2025) — NeuroWave Systems Inc. announced the issuance of U.S. Patent No. 12,377,215, “Intelligent Pharmaceutical Delivery System with Automatic Shutoff and Method of Using.” The patent protects technology foundational to SEDGuard™, the first application of NeuroWave’s Intelligent Therapeutic Platform (ITP), which brings together brain monitoring, intelligent control, and infusion technology to support physiologically guided drug delivery.

The patent covers systems that monitor electroencephalographic (EEG) activity, detect burst suppression, and automatically reduce anesthetic or sedative administration based on the detected suppression. This approach connects continuous measurement of the brain’s response to medication with an automated therapeutic action.

SEDGuard is being developed as a continuously active safety layer for sedation management in critically ill patients. It combines NeuroSENSE® brain-monitoring technology with an infusion system and supervisory control software. When excessive EEG suppression is detected, SEDGuard is designed to reduce sedative delivery within clinician-prescribed limits and return toward the prescribed nominal infusion rate when suppression resolves. Clinicians retain control over the sedation strategy, dosing boundaries, and automated intervention.

“This patent is foundational to SEDGuard and to our vision for intelligent therapeutic systems that respond to each patient’s physiology,” said Dr. Stephane Bibian, NeuroWave’s Vice President of Engineering and a co-inventor of the patent. “A sedative dose that is appropriate at one point may become excessive as a critically ill patient’s condition changes. By continuously monitoring the brain’s response and linking that information to drug delivery, SEDGuard is intended to respond to excessive sedative effect between bedside assessments within clinicians’ defined boundaries.”

The technology may be particularly valuable for mechanically ventilated patients receiving prolonged sedation, including those receiving neuromuscular blocking agents, for whom behavioral sedation assessments cannot be performed. It also addresses settings where frequent assessments are difficult because of staffing constraints, high clinical workload, or isolation precautions associated with infectious diseases.

“This award complements NeuroWave’s growing intellectual property portfolio spanning EEG monitoring, infusion technologies, and intelligent therapeutics,” said Brian Kolkowski, NeuroWave’s intellectual property counsel and Executive VP of Business Development. “We are particularly pleased with the patent-term adjustment of approximately 5 years reflected on the issued patent. Protecting the technologies that connect physiologic sensing with therapeutic delivery is an important part of supporting NeuroWave’s continued development and commercialization efforts.”

SEDGuard is under development with the aim of reducing unnecessary sedative exposure while preserving clinician-directed care. It represents the first application of a broader platform designed to translate continuous physiologic information into timely therapeutic action.

About NeuroWave:

NeuroWave Systems Inc.'s mission is to develop, manufacture & market innovative monitoring & drug delivery medical devices using advanced neurophysiological signal processing & control system engineering for Anesthesia, Critical Care, and Military Medicine, to improve patient safety, outcome and quality of life.

For further information regarding NeuroWave Systems Inc., visit the Company's website at www.neurowavesystems.com.

NeuroSENSE is a registered trademark of NeuroWave Systems Inc., Beachwood, Ohio.

SEDGuard is a trademark of NeuroWave Systems Inc., Beachwood, Ohio.